A British Medical Journal (BMJ) report on November 2, 2021, about a whistleblower, Brook Jackson, who alleges the Texas-based Ventavia Research Group, a contractor involved in Pfizer’s phase III trial for COVID-19 vaccine in 2020, “falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial.”
Brook emailed the FDA in September 2020, the FDA took no action on her email but Ventavia fired her. [2]
In January 8, 2021 Broke filed her “federal complaint under the False Claims Act, after first warning the U.S. Food and Drug Administration (FDA) of significant concerns she witnessed.” [1]
In May 2022, the Epoch Times reported that Pfizer argued in court that the company did not violate its contract because its agreement with the U.S. Department of Defense allowed them to skirt the rules.
The TGA believe this Pfizer claim represents “only 2% of the trial population”. This statement by TGA spokesperson proves that they use global data from the sponsor to make assessments for vaccine Provisional approval in Australia.
Other vaccine trial participants with “unwanted” outcomes are also known to have been removed from trial datasets.